agreed.
RHT
- have 5 approved FDA products. Not many biotechs that produce consistent positive cash flow, and are growing in assets and revenue yearly
- Management are very sound and keep capital expenditure to a minimum.
- substantial holder bought $2-3mill at 20c+ when SP was 10c
- applied for FDA in April for HepaFat-Al, an AI software that aids in managing liver disease and liver transplants. When I called up - management said they were “highly confident” in receiving FDA approval
- management of RHT are sound and I’m guessing FDA have an amazing relationship with them for all their 5 products to have received FDA approval coupled by the fundamentals of their products
- Discl: bought 14c
- Forums
- ASX - By Stock
- RHT
- Ann: 510(k) Application Submission to U.S. FDA
Ann: 510(k) Application Submission to U.S. FDA, page-67
-
- There are more pages in this discussion • 34 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RHT (ASX) to my watchlist
(20min delay)
|
|||||
Last
5.9¢ |
Change
-0.004(6.35%) |
Mkt cap ! $26.36M |
Open | High | Low | Value | Volume |
6.0¢ | 6.0¢ | 5.9¢ | $2.087K | 35.11K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 68512 | 5.9¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
6.2¢ | 660000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 68512 | 0.059 |
2 | 150000 | 0.058 |
4 | 639999 | 0.056 |
2 | 219999 | 0.050 |
1 | 500000 | 0.049 |
Price($) | Vol. | No. |
---|---|---|
0.062 | 660000 | 1 |
0.063 | 517920 | 1 |
0.064 | 15765 | 1 |
0.065 | 55000 | 2 |
0.066 | 25000 | 1 |
Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
Featured News
RHT (ASX) Chart |